Heart surgeons endorse xenotransplantation

A survey of attitudes among heart surgeons shows most are supportive of xenotransplantation.

According to a new survey, more than 80% of heart surgeons believe the potential acceptance of xenotransplantation would be high if it can demonstrate reasonable results [1]. The study comes as researchers around the world are seeking new ways to increase the supply of organs to younger heart patients.

Longevity.Technology: A scarcity of donors means that many young heart disease patients will never receive life-saving transplants. Xenotransplantation is one of the most promising avenues to increase organ supply, but uncertainty remains around the retrovirus risks or how surgeons would greet the prospect if it became available.

Recent years have seen a significant improvement in mortality rates for heart transplants however challenges remain [2]. Transplantation for young children is hampered by the scarcity of donors, waiting list mortality rates remain high with one of the biggest challenges being a lack of support options for patients with single ventricle physiology [3]. However, advances in xenotransplantation in which live tissue is transplanted from pigs to humans suggest it could provide a viable alternative [4].

Back in June last year we reported that researchers from Harvard and eGenesis had used  CRISPR to genetically remove retroviruses to make pigs organs viable for human transplantation; and that eGenesis announced it has raised $100 million in a series B funding round, led by venture capital firm Fresenius Medical Care, one of the world’s leading companies in end stage and chronic kidney disease treatment.

Now, as the Xeno market progresses, this study attempted to understand attitudes among heart surgeons towards the procedure. To do so they sent a Likert scale anonymous survey to members of the Congenital Heart Surgeons Society and the Pediatric Heart Transplant Society.

In total, 92 surgeons responded from the CHS and 42 responded from the PTC. Both groups showed a high acceptance (88% and 81% respectively) assuming results could be shown to be similar to those of cardiac allotransplantation.

Those numbers came down considerably when asked to assume results were shown to be inferior to cardiac allotransplantation, with only 41% of surgeons from the CHS and 17% of surgeons from the PTC, saying they would support it. A third of CHS and half of PTC respondents preferred primary cardiac xenotransplantation for hypoplastic left heart syndrome if it has similar outcomes to allotransplantation and there was no waiting list time.

Research into xenotransplantation is still ongoing, but this study shows clinical acceptance would not be a major barrier as long as studies show it can offer comparative results to existing methods.

[1] https://journals.sagepub.com/doi/abs/10.1177/2150135120916744
[2] https://srtr.transplant.hrsa.gov/annual_reports/2017/Heart.aspx
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827130/
[4] https://www.scientificamerican.com/article/baboons-survive-for-half-a-year-after-heart-transplants-from-pigs/

Image by Sasin Tipchai from Pixabay
Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

GDF15 protects from age‐related metabolic phenotypes

A recent study shows an important role for GDF15 in preventing aging-induced metabolic phenotypes by modulating systemic inflammatory responses in humans and mice. Dysfunction of...